The latest settlement involves a practice known as ‘off-label marketing’ in which drugmakers push medicines for uses beyond those approved by the regulator.
Connecticut and 43 other states have joined in a settlement with the British pharmaceutical firm GlaxoSmithKline (GSK) to resolve allegations of unlawful promotion of the asthma drug, Advair, and antidepressants Paxil and Wellbutrin.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
